GO:0000334 3-hydroxyanthranilate 3,4-dioxygenase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0000334 describes the enzymatic activity that converts 3-hydroxyanthranilate and oxygen into cis,cis-2-amino-3-(3-oxoprop-1-enyl)but-2-enedioate, a key step in the kynurenine pathway.
• The enzyme is a non-heme Fe(II)-dependent dioxygenase that opens the aromatic ring of 3-hydroxyanthranilate, committing the metabolite to quinolinic acid and NAD+ biosynthesis.
• Human 3-hydroxyanthranilate 3,4-dioxygenase (3HAO) is a mononuclear iron enzyme whose catalytic cycle involves substrate binding, oxygen activation, and ring cleavage.
• Dysregulation of 3HAO activity is linked to neurological conditions such as epilepsy and to NAD+ deficiency disorders.
• Edaravone and other small molecules can directly inhibit 3HAO, reducing quinolinic acid formation, which is relevant for neuroprotection.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable precise interrogation of 3HAO function in health and disease.
Description
3-hydroxyanthranilate 3,4-dioxygenase activity (GO:0000334) is a molecular function that catalyzes the oxidative ring cleavage of 3-hydroxyanthranilate to cis,cis-2-amino-3-(3-oxoprop-1-enyl)but-2-enedioate, a central reaction in the kynurenine pathway. This activity is essential for the de novo synthesis of NAD+ from tryptophan and for the production of the neuroactive metabolite quinolinic acid. Researchers study this enzyme because its product, quinolinic acid, is a potent NMDA receptor agonist implicated in excitotoxicity, and because the enzyme itself is a potential drug target for modulating NAD+ levels and neuroinflammation. The reaction is catalyzed by non-heme Fe(II)-dependent dioxygenases that are conserved from bacteria to humans. Structural and mechanistic studies have revealed that the enzyme undergoes a conformational change upon substrate binding and uses a ferrous iron center to activate molecular oxygen. In this article, we provide a comprehensive overview of GO:0000334, covering its definition, mechanism, key genes, disease associations, and modern research methods including CRISPR-based models.
3-hydroxyanthranilate 3,4-dioxygenase activity At A Glance
| GO ID | GO:0000334 |
|---|---|
| GO term | 3-hydroxyanthranilate 3,4-dioxygenase activity |
| Ontology | molecular_function |
| Synonym | 3HAO, 3-hydroxyanthranilate:oxygen 3,4-oxidoreductase (decyclizing), 3-hydroxyanthranilate oxygenase activity, 3-hydroxyanthranilic acid dioxygenase activity, 3-hydroxyanthranilic acid oxygenase activity, 3-hydroxyanthranilic oxygenase activity |
| Definition | Catalysis of the reaction: 3-hydroxyanthranilate + O2 = cis,cis-2-amino-3-(3-oxoprop-1-enyl)but-2-enedioate + H+. |
| Major function | Oxidative ring cleavage of 3-hydroxyanthranilate in the kynurenine pathway, leading to quinolinic acid and NAD+ biosynthesis. |
| Cofactor | Non-heme ferrous iron (Fe2+). |
| Subcellular location | Cytosol (in eukaryotes). |
| Pathway | Kynurenine pathway (tryptophan catabolism). |
What Is GO:0000334?
According to the Gene Ontology, GO:0000334 (3-hydroxyanthranilate 3,4-dioxygenase activity) is defined as the catalysis of the reaction: 3-hydroxyanthranilate + O2 = cis,cis-2-amino-3-(3-oxoprop-1-enyl)but-2-enedioate + H+. In simpler terms, this activity describes an enzyme that uses oxygen to break open the aromatic ring of 3-hydroxyanthranilate, producing an acyclic product. This is a dioxygenase reaction, meaning both atoms of molecular oxygen are incorporated into the product. The enzyme belongs to the family of non-heme iron-dependent dioxygenases and requires a ferrous iron cofactor for activity.
Why Is 3-hydroxyanthranilate 3,4-dioxygenase activity Important in Cell Biology?
GO:0000334 is critical because it represents a committed step in the kynurenine pathway, directing tryptophan metabolites toward quinolinic acid and NAD+ synthesis. The enzyme product, quinolinic acid, is a neuroactive compound that can cause excitotoxicity at high concentrations, linking this activity to neurodegenerative and seizure disorders. Moreover, the enzyme is a potential therapeutic target: inhibiting 3HAO can reduce quinolinic acid production, which may be beneficial in neuroinflammatory conditions. Additionally, mutations affecting this pathway can lead to NAD+ deficiency and congenital malformations, highlighting its role in human development. Thus, understanding 3HAO activity is essential for both basic biochemistry and translational medicine.
• Central to the kynurenine pathway, controlling flux toward quinolinic acid and NAD+.
• Quinolinic acid is an NMDA receptor agonist implicated in excitotoxicity and neurodegeneration.
• Enzyme inhibition by edaravone reduces quinolinic acid, suggesting therapeutic potential.
• Defects in the pathway cause NAD+ deficiency and congenital malformations.
• 3HAO is a non-heme iron enzyme, serving as a model for dioxygenase mechanisms.
• Abnormally high 3HAO activity is observed in epilepsy-prone animal models.
• The enzyme is conserved from bacteria to humans, with prokaryotic homologs in degradation pathways.
• Structural studies reveal conformational changes and metal coordination essential for catalysis.
• Small-molecule inhibitors can directly target 3HAO, offering pharmacological tools.
• CRISPR screens can identify regulators of 3HAO expression or activity.
Molecular Mechanism of 3-hydroxyanthranilate 3,4-dioxygenase activity
Substrate Binding and Conformational Change
In simple terms: The enzyme changes shape to grab its substrate.
Crystal structures of human 3HAO have shown that the enzyme undergoes a significant conformational change upon binding of 3-hydroxyanthranilate, closing the active site around the substrate. This induced fit positions the substrate near the ferrous iron cofactor for catalysis. The substrate binds in a hydrophobic pocket, and its carboxylate group interacts with conserved residues, ensuring specificity.
Iron Coordination and Oxygen Activation
In simple terms: An iron atom in the enzyme helps activate oxygen to break the substrate ring.
The active site contains a mononuclear non-heme ferrous iron coordinated by conserved histidine and glutamate residues. Molecular oxygen binds to the iron, forming a ferrous-dioxygen species that attacks the aromatic ring of 3-hydroxyanthranilate. This step is rate-limiting and is influenced by the metal's redox state.
Ring Cleavage and Product Release
In simple terms: The enzyme breaks the ring and releases the product.
Following oxygen activation, the enzyme catalyzes the cleavage of the C3-C4 bond of 3-hydroxyanthranilate, yielding cis,cis-2-amino-3-(3-oxoprop-1-enyl)but-2-enedioate. The product is then released, and the enzyme returns to its resting state. This reaction is irreversible and commits the metabolite to the quinolinic acid branch.
Inactivation and Inhibition
In simple terms: Certain molecules can block the enzyme.
4-chloro-3-hydroxyanthranilate acts as a mechanism-based inactivator, covalently modifying the enzyme and abolishing activity. Edaravone directly inhibits 3HAO, reducing quinolinic acid formation in vitro. These inhibitors are valuable for probing enzyme function and for therapeutic development.
Key Genes Involved in GO:0000334 3-hydroxyanthranilate 3,4-dioxygenase activity
The following genes and proteins are directly involved in 3-hydroxyanthranilate 3,4-dioxygenase activity or its regulation.
| Gene | Major Role | Research Relevance |
|---|---|---|
| HAAO | Encodes human 3-hydroxyanthranilate 3,4-dioxygenase | Mutations cause NAD+ deficiency and congenital malformations |
| HAAO (bacterial homolog) | Prokaryotic 3HAO in 2-nitrobenzoate degradation | Model for enzyme mechanism and evolution |
| BNA6 | Yeast homolog of 3HAO | Genetic studies of NAD+ biosynthesis |
| QPRT | Quinolinate phosphoribosyltransferase, downstream enzyme | Links 3HAO product to NAD+ synthesis |
| KMO | Kynurenine 3-monooxygenase, upstream enzyme | Regulates flux into 3HAO pathway |
| KYNU | Kynureninase, upstream enzyme | Provides substrate for 3HAO |
| TDO2 | Tryptophan 2,3-dioxygenase, first step of kynurenine pathway | Controls tryptophan catabolism |
| IDO1 | Indoleamine 2,3-dioxygenase, alternative first step | Immune regulation and tryptophan depletion |
| ACMSD | 2-amino-3-carboxymuconate-6-semialdehyde decarboxylase | Competes with spontaneous cyclization to quinolinic acid |
| NADSYN1 | NAD synthetase, downstream of 3HAO | NAD+ production |
| NMNAT | Nicotinamide mononucleotide adenylyltransferase | NAD+ salvage and synthesis |
| SLC7A11 | Cystine/glutamate antiporter, affects redox | Indirectly influences 3HAO activity via oxidative stress |
| GCLM | Glutamate-cysteine ligase modifier subunit | Redox regulation of 3HAO |
| NFE2L2 | NRF2, transcription factor | Regulates antioxidant response, may affect 3HAO expression |
| HIF1A | Hypoxia-inducible factor 1-alpha | May regulate kynurenine pathway genes under hypoxia |
| AHR | Aryl hydrocarbon receptor | Modulates kynurenine pathway and immune response |
| CASP1 | Caspase-1, inflammasome | Inflammation-induced kynurenine pathway activation |
| IL1B | Interleukin-1 beta | Pro-inflammatory cytokine inducing IDO1 and kynurenine pathway |
How Is 3-hydroxyanthranilate 3,4-dioxygenase activity Regulated?
3-hydroxyanthranilate 3,4-dioxygenase activity is regulated at multiple levels. Transcriptionally, the HAAO gene can be influenced by inflammatory signals and transcription factors such as AHR and NRF2, which modulate kynurenine pathway flux. Post-translationally, the enzyme requires ferrous iron for activity, and its metalation state is sensitive to cellular iron availability and oxidative stress. Additionally, the enzyme can be inhibited by small molecules like edaravone, which directly binds and reduces its catalytic efficiency. In epilepsy-prone mice, abnormally high 3HAO activity suggests disease-specific dysregulation. Furthermore, NAD+ levels feedback to regulate the pathway, though direct allosteric regulation of 3HAO by NAD+ has not been reported.
3-hydroxyanthranilate 3,4-dioxygenase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| HAAO | NAD+ deficiency with congenital malformations | HAAO knockout mouse, patient iPSCs |
| HAAO | Epilepsy (increased activity) | El mouse model, HAAO overexpression |
| QPRT | Neurodegeneration (quinolinic acid accumulation) | QPRT knockout, 3HAO inhibitor treatment |
| KMO | Huntington's disease (kynurenine pathway dysregulation) | KMO knockout mice, CRISPR point mutations |
| IDO1 | Cancer immune evasion | IDO1 knockout tumor models, CRISPR screens |
Epilepsy and Seizure Disorders
In epilepsy-prone El mice, 3HAO activity is abnormally high in the brain, leading to increased quinolinic acid production, which may contribute to seizure susceptibility. This suggests that 3HAO inhibitors could have anticonvulsant potential.
NAD+ Deficiency and Congenital Malformations
Mutations in HAAO, the gene encoding 3HAO, cause NAD+ deficiency, which can result in congenital malformations such as vertebral, cardiac, renal, and limb defects. Niacin supplementation can rescue these defects in animal models, highlighting the importance of the pathway in development.
Neurodegeneration and Excitotoxicity
Quinolinic acid, the product of 3HAO, is a neurotoxin that acts as an NMDA receptor agonist, contributing to excitotoxic neuronal death in conditions like Alzheimer's disease and Huntington's disease. Inhibiting 3HAO reduces quinolinic acid levels, offering a neuroprotective strategy.
Cancer and Immune Regulation
The kynurenine pathway, including 3HAO, is often dysregulated in cancer, where it contributes to immune suppression and tumor progression. Targeting this pathway is an active area of immuno-oncology research.
From 3-hydroxyanthranilate 3,4-dioxygenase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| What is the effect of 3HAO loss on NAD+ levels? | HAAO knockout cell lines (e.g., HEK293, HepG2) |
| How does a disease-associated point mutation affect enzyme activity? | Knock-in of mutant HAAO (e.g., patient variants) |
| Can a tagged 3HAO be used to study localization and interactions? | Knock-in of FLAG- or GFP-tagged HAAO |
| What is the effect of 3HAO overexpression on quinolinic acid production? | Overexpression of HAAO in neuronal cell lines |
| Which genes regulate 3HAO expression? | CRISPR library screening with a 3HAO reporter |
| Can 3HAO inhibitors rescue neurotoxicity? | Primary neurons treated with edaravone and 3HAO overexpression |
How to Study the 3-hydroxyanthranilate 3,4-dioxygenase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Spectrophotometric assay | 3HAO enzymatic activity | Kinetic studies, inhibitor screening |
| HPLC | Quinolinic acid levels | Pathway flux analysis |
| X-ray crystallography | Protein structure | Mechanistic insights, drug design |
| Molecular dynamics | Protein dynamics and reaction | Computational enzymology |
| CRISPR knockout screen | Gene essentiality and regulators | Identify modifiers of 3HAO expression |
| Western blot | Protein expression levels | Validate knockout or overexpression |
| Immunofluorescence | Subcellular localization | Confirm cytosolic localization |
| RNA-seq | Transcriptional changes | Pathway analysis upon 3HAO perturbation |
Enzymatic Activity Assays
3HAO activity can be measured spectrophotometrically by monitoring the formation of the product at 360 nm or by HPLC-based quantification of quinolinic acid. These assays are used to determine kinetic parameters and to test inhibitors like edaravone.
Structural Biology
X-ray crystallography of human 3HAO with native and non-native metals has revealed the active site architecture and conformational changes upon substrate binding. These studies guide the design of specific inhibitors.
Computational Modeling
Molecular dynamics simulations and quantum mechanics/molecular mechanics (QM/MM) studies have provided insights into the reaction mechanism and dynamics of human 3HAO. Such models complement experimental structures.
CRISPR-Based Genetic Screens
Genome-wide CRISPR knockout or activation screens can identify regulators of 3HAO expression or activity. For example, a reporter cell line expressing 3HAO-driven luciferase can be used to screen for modifiers.
How CRISPR Can Be Used to Study GO:0000334 3-hydroxyanthranilate 3,4-dioxygenase activity
Knockout
CRISPR-Cas9 knockout of HAAO can completely abolish 3HAO activity, leading to reduced quinolinic acid and NAD+ depletion. Such models are valuable for studying the consequences of pathway blockade and for validating drug targets.
Point Mutation
Introducing patient-derived point mutations into HAAO via CRISPR base editing or homology-directed repair allows assessment of their impact on enzyme activity and stability. This is particularly relevant for HAAO variants associated with congenital malformations.
Knock-in
Knock-in of epitope tags (e.g., FLAG, HA) or fluorescent proteins (e.g., GFP) into the endogenous HAAO locus enables real-time tracking of protein localization and interaction without overexpression artifacts.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of HAAO can elevate 3HAO activity, increasing quinolinic acid production. This is useful for modeling excitotoxicity and for screening protective compounds.
How EDITGENE Supports 3-hydroxyanthranilate 3,4-dioxygenase activity Research
Researchers studying 3-hydroxyanthranilate 3,4-dioxygenase activity-related genes often need to determine whether a candidate gene is causally involved in pathway regulation, disease pathogenesis, or drug response. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate such investigations, from gene knockout to precise point mutations and library screens.
Contact EDITGENE today to design your custom CRISPR model for 3-hydroxyanthranilate 3,4-dioxygenase activity research.
Frequently Asked Questions About 3-hydroxyanthranilate 3,4-dioxygenase activity
What is 3-hydroxyanthranilate 3,4-dioxygenase activity?
It is the enzymatic activity (GO:0000334) that catalyzes the conversion of 3-hydroxyanthranilate and oxygen to cis,cis-2-amino-3-(3-oxoprop-1-enyl)but-2-enedioate, a step in the kynurenine pathway.
What genes are involved in 3-hydroxyanthranilate 3,4-dioxygenase activity?
The primary gene is HAAO, which encodes the enzyme. Other pathway genes include KYNU, KMO, QPRT, and IDO1.
What is the function of HAAO?
HAAO encodes 3-hydroxyanthranilate 3,4-dioxygenase, which produces quinolinic acid, a precursor to NAD+ and a neurotoxin.
How is 3-hydroxyanthranilate 3,4-dioxygenase activity measured?
It can be measured by spectrophotometric assays monitoring product formation or by HPLC quantification of quinolinic acid.
What diseases are associated with 3-hydroxyanthranilate 3,4-dioxygenase?
Mutations in HAAO cause NAD+ deficiency and congenital malformations; elevated activity is linked to epilepsy and neurodegeneration.
Can 3-hydroxyanthranilate 3,4-dioxygenase be inhibited?
Yes, compounds like edaravone and 4-chloro-3-hydroxyanthranilate inhibit the enzyme, reducing quinolinic acid production.
What is the role of iron in 3-hydroxyanthranilate 3,4-dioxygenase?
The enzyme requires a non-heme ferrous iron cofactor to activate oxygen and catalyze ring cleavage.
How can CRISPR be used to study 3-hydroxyanthranilate 3,4-dioxygenase?
CRISPR knockout, point mutation, knock-in, and overexpression models allow precise manipulation of HAAO to study its function and disease relevance.
Is 3-hydroxyanthranilate 3,4-dioxygenase a drug target?
Yes, inhibiting the enzyme may reduce neurotoxic quinolinic acid, making it a target for neuroprotection.
What is the kynurenine pathway?
It is the metabolic route that converts tryptophan to NAD+ and produces neuroactive intermediates including quinolinic acid; 3HAO is a key enzyme in this pathway.
Conclusion
3-hydroxyanthranilate 3,4-dioxygenase activity (GO:0000334) is a fundamental enzymatic function in the kynurenine pathway, bridging tryptophan metabolism to NAD+ synthesis and quinolinic acid production. Its dysregulation is implicated in epilepsy, congenital malformations, and neurodegeneration, making it a compelling target for therapeutic intervention. Advances in structural biology and CRISPR-based models continue to unravel its mechanism and regulation, offering new opportunities for drug discovery and precision medicine. Researchers can leverage EDITGENE's services to generate custom cell models and accelerate their investigations into this critical enzyme.
References
- 1. Wang Y et al.. 2020. Observing 3-hydroxyanthranilate-3,4-dioxygenase in action through a crystalline lens.. Proc Natl Acad Sci U S A 117(33):19720-19730 PMID: 32732435
- 2. Sanz I et al.. 2022. Chromatographic measurement of 3-hydroxyanthranilate 3,4-dioxygenase activity reveals that edaravone can mitigate the formation of quinolinic acid through a direct enzyme inhibition.. J Pharm Biomed Anal 219:114948 PMID: 35907317
- 3. Brkić H et al.. 2015. Human 3-hydroxyanthranilate 3,4-dioxygenase () dynamics and reaction, a multilevel computational study.. Mol Biosyst 11(3):898-907 PMID: 25588817
- 4. Nakano K et al.. 1992. Abnormally high activity of 3-hydroxyanthranilate 3,4-dioxygenase in brain of epilepsy-prone El mice.. Brain Res 572(1-2):1-4 PMID: 1611505
- 5. Pidugu LS et al.. 2017. Crystal structures of human 3-hydroxyanthranilate 3,4-dioxygenase with native and non-native metals bound in the active site.. Acta Crystallogr D Struct Biol 73(Pt 4):340-348 PMID: 28375145
- 6. Colabroy KL et al.. 2005. The mechanism of inactivation of 3-hydroxyanthranilate-3,4-dioxygenase by 4-chloro-3-hydroxyanthranilate.. Biochemistry 44(21):7623-31 PMID: 15909977
- 7. Muraki T et al.. 2003. Prokaryotic homologs of the eukaryotic 3-hydroxyanthranilate 3,4-dioxygenase and 2-amino-3-carboxymuconate-6-semialdehyde decarboxylase in the 2-nitrobenzoate degradation pathway of Pseudomonas fluorescens strain KU-7.. Appl Environ Microbiol 69(3):1564-72 PMID: 12620844
- 8. Shi H et al.. 2017. NAD Deficiency, Congenital Malformations, and Niacin Supplementation.. N Engl J Med 377(6):544-552 PMID: 28792876
